胶质瘤患者血清外泌体microRNA特征可作为补充诊断生物标志物
研究采集高、低级别胶质瘤患者手术前后及健康对照的血清外泌体,检测miR-21、miR-222和miR-124-3p表达;高级别胶质瘤患者这三种microRNA表达显著高于低级别胶质瘤和健康对照,且术后样本中急剧下降;作者认为血清外泌体microRNA分析可作为微创工具辅助胶质瘤鉴别诊断、预测分级及术前排除非胶质转移。
要点
- 高级别胶质瘤患者血清外泌体miR-21、miR-222和miR-124-3p表达显著高于低级别胶质瘤和健康对照。
- 手术切除后血清外泌体中这三种microRNA表达水平急剧下降。
- 作者认为血清外泌体microRNA分析可作为微创工具辅助胶质瘤鉴别诊断和分级预测。
核心结论
- 血清外泌体中miR-21、miR-222和miR-124-3p的分析可为胶质瘤的微创诊断提供创新工具,帮助胶质瘤初发时的鉴别诊断、预测胶质瘤分级及术前判断非胶质转移。
研究设计与样本
- 研究收集高、低级别胶质瘤患者手术前后及健康对照的血液样本,检测血清外泌体中miR-21、miR-222和miR-124-3p的表达。
主要发现
- 高级别胶质瘤患者血清外泌体miR-21、miR-222和miR-124-3p表达显著高于低级别胶质瘤患者和健康对照。
- 手术切除后获得的血清外泌体样本中miR-21、miR-222和miR-124-3p表达急剧下降。
临床怎么用
- 作者认为血清外泌体miR-21、miR-222和miR-124-3p分析可作为微创工具,辅助胶质瘤初发时的鉴别诊断、预测胶质瘤分级及术前判断非胶质转移。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Malignant gliomas, the most frequent primary brain tumors, are characterized by a dismal prognosis. Reliable biomarkers complementary to neuroradiology in the differential diagnosis of gliomas and monitoring for post-surgical progression are unmet needs. Altered expression of several microRNAs in tumour tissues from patients with gliomas compared to normal brain tissue have been described, thus supporting the rationale of using microRNA-based biomarkers. Although different circulating microRNAs were proposed in association with gliomas, they have not been introduced into clinical practice so far. Blood samples were collected from patients with high and low grade gliomas, both before and after surgical resection, and the expression of miR-21, miR-222 and miR-124-3p was measured in exosomes isolated from serum. The expression levels of miR-21, miR-222 and miR-124-3p in serum exosomes of patients with high grade gliomas were significantly higher than those of low grade gliomas and healthy controls and were sharply decreased in samples obtained after surgery. The analysis of miR-21, miR-222 and miR-124-3p in serum exosomes of patients affected by gliomas can provide a minimally invasive and innovative tool to help the differential diagnosis of gliomas at their onset in the brain and predict glioma grading and non glial metastases before surgery.
引用
- Santangelo A, Imbrucè P, Gardenghi B, et al. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2017. PMID: 29076001. doi:10.1007/s11060-017-2639-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。